

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500034. Telangana, India.

CONTACT	
INVESTOR RELATIONS	MEDIA RELATIONS
AISHWARYA SITHARAM AISHWARYASITHARAM@DRREDDYS.COM	PRIYA K PRIYAK@DRREDDYS.COM

Dr. Reddy's Laboratories Announces Launch of Oral Semaglutide Biosimilar 'Obeda®' (tablets) in India

Hyderabad, India, May 20, 2026 – Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy's"), a global pharmaceutical company, today announced the launch of its oral semaglutide biosimilar, indicated for type 2 diabetes mellitus. Dr. Reddy's oral semaglutide is available in tablet form under the brand name Obeda® in India. This launch follows Dr. Reddy's recent generic Semaglutide injection launches in India and Canada, further establishing the company's position as a full-stack player in GLP-1 therapies.

As per the ICMR-INDIAB study, India represents one of the world's largest diabetes burdens with over 101 million adults living with the condition and a prevalence of 11.4%. Alarming, nearly 136 million individuals are prediabetic, and close to 40% of adults have abdominal obesity, placing them at high risk of progression¹. Despite multiple treatment options, uncontrolled type 2 diabetes remains a significant challenge. Oral semaglutide, a Glucagon-Like Peptide-1 receptor agonist (GLP-1 RA), is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. It can offer convenient, and flexible option which may support earlier treatment initiation, improving adherence and helping reduce the risk of long-term complications².

Dr. Reddy's Obeda® (semaglutide tablets) is formulated using recombinant DNA (rDNA) origin of semaglutide active pharmaceutical ingredient (API). Dr. Reddy's obtained approval for its oral semaglutide biosimilar from the CDSCO following a review of a Phase III clinical study enrolling 288 participants with type 2 diabetes mellitus conducted in India, which demonstrated non-inferior efficacy and a safety profile comparable to the innovator oral drug. Similar results were seen for fasting and post-prandial plasma glucose, weight loss, and overall glycemic control, as measured by the proportion of participants achieving an HbA1c level below 7% at 12 and 24 weeks. Further, no anti-drug antibodies were detected, and the immunogenicity profile was comparable to that of the innovator drug³.

Dr. Reddy's Obeda® (semaglutide tablets) is available in 3 mg, 7 mg and 14 mg strengths and recommended for once-daily oral use. It is priced at Rs. 99, Rs. 135, and Rs. 225 per tablet for the 3 mg, 7 mg, and 14 mg doses, respectively.

¹ <https://idf.org/about-diabetes/diabetes-facts-figures/>

² <https://doi.org/10.1016/j.clinthera.2024.11.005>

³ Dr. Reddy's Laboratories Ltd's Obeda® (oral semaglutide) prescribing information April 2026

M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy's, said: "The launch of our oral semaglutide for patients with diabetes marks an important step in our journey to broaden access to advanced diabetes care. We recognize that every patient's journey with diabetes is different, and treatment choices must reflect that diversity. With this launch, we are broadening our GLP-1 portfolio to offer patients more choice and flexibility. As the product is developed and formulated in-house, we are committed to reliable supply and consistent quality for patients in India. As we continue to build a comprehensive GLP-1 portfolio, we are focused on delivering innovation, high-quality, and affordability, translating into meaningful treatment options and better long-term outcomes for people living with chronic metabolic diseases in India and beyond."

Dr. Reddy's Obeda® (semaglutide tablets) is a prescription-based drug. Patients are advised to consult their doctors for more details.

.....
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait,' we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.

For more information, log on to: www.drreddys.com.

.....
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2025. The company assumes no obligation to update any information contained herein.